AltheRx acquires Solabegron from GSK

AltheRx Pharmaceuticals Inc. (Chadds Ford, Pa.) acquired Solabegron ( GW427353) from GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) for an undisclosed amount. AltheRx plans to begin Phase III testing of the adrenergic receptor beta 3 agonist ( ADRB3) for overactive bladder (OAB) by year end. The company also is planning a Phase IIb trial of the compound in irritable bowel syndrome (IBS), but did not provide guidance on when the trial would start. GSK told BioCentury that it sold the program because it did not fit in its strategic portfolio. ...